Cost-effectiveness of frequent HIV testing of high-risk populations in the United States

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 3, 2016, Pages 323-330

  Hutchinson, Angela B ^a   Farnham, Paul G ^a   Sansom, Stephanie L ^a   Yaylali, Emine ^a   Mermin, Jonathan H ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cost effectiveness; HIV testing; Injection drug users; Men who have sex with men; Test frequency

Indexed keywords

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG USE; HEALTH CARE AVAILABILITY; HIGH RISK POPULATION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MEN WHO HAVE SEX WITH MEN; NONHUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RAPID TEST; UNITED STATES; VIRUS LOAD; VIRUS TRANSMISSION; COHORT ANALYSIS; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; HIV INFECTIONS; MALE; MALE HOMOSEXUALITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE; TIME FACTOR; TRANSMISSION;

COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; POINT-OF-CARE TESTING; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; UNITED STATES;

EID: 84959149412     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000838     Document Type: Article

References (49)

1. CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data - United States and 6 dependent areas - 2012. HIV Surveillance Supplemental Report. Atlanta, Georgia: Centers for Disease Control and Prevention; 2014.
2. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447-1450.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365: 493-505.
4. Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS. 2012;26:893-896.
5. CDC. HIV Surveillance Report, 2011.
6. Broz D, Wejnert C, Pham HT. HIV infection and risk, prevention, and testing behaviors among injecting drug users - national HIV behavioral surveillance system, 20 U.S. Cities, 2009. Morb Mortal Wkly Rep. 2014; 63:1-51.
7. CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006; 55:1-17; quiz CE11-14.
8. CDC. HIV testing among men who have sex with men - 21 cities, United States, 2008. Morb Mortal Wkly Rep. 2011;60:694-699.
9. Branson BM, Mermin J. Establishing the diagnosis of HIV infection: new tests and a new algorithm for the United States. J Clin Virol. 2011; 52(suppl 1):S3-S4.
10. Branson BM. The future of HIV testing. J Acquir Immune Defic Syndr. 2010;55(suppl 2):S102-S105.
11. FDA. August 9, 2013 Approval Letter - Alere Determine HIV-1/2 Ag/Ab Combo. Rockville, MD: U.S. Food and Drug Administration; 2013.
12. PR Newswire. U.S. Food and Drug Administration Grants CLIA Waiver for Alere Determine™ HIV-1/2 Ag/Ab Combo Test. Waltham, MA: PR Newswire; 2014.
13. Long EF. HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis. PLoS One. 2011;6(11):e27625.
14. Cipriano LE, Zaric GS, Holodniy M, et al. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One. 2012;7:e45176.
15. Hutchinson AB, Patel P, Sansom SL, et al. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after thirdgeneration HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med. 2010;7:e1000342.
16. Hutchinson AB, Farnham PG, Duffy N, et al. Return on public health Investment: CDC's expanded HIV testing Initiative. J Acquir Immune Defic Syndr. 2011;59:281-286.
17. Huang A, Hutchinson A, Hollis ND, et al. Notification following new positive HIV test results. Int J STDS AIDS. 2015. [Epub ahead of print].
18. Yaylali E, Farnham P, Schneider KD, et al. From theory to practice: implementation of a resource allocation model in health departments. J Public Health Manag Pract. 2015. [Epub ahead of print].
19. CDC. Men living with diagnosed HIV who have sex with men: progress along the continuum of HIV care - United States. Morb Mortal Wkly Rep. 2014;63:829-833.
20. CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data - United States and 6 U.S. dependent areas - 2011. HIV Surveillance Supplemental Report. Atlanta, Georgia: Centers for Disease Control and Prevention; 2013.
21. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. Open AIDS J. 2012;6:98-107.
22. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6:e17502.
23. Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One. 2014;9: e97596.
24. Tempalski B, Lieb S, Cleland CM, et al. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002. J Urban Health. 2009;86:132-154.
25. Pinkerton SDHD. A method for evaluating the economic efficiency of HIV behavioral risk reduction interventions. AIDS Behav. 1998;2:189-201.
26. Pinkerton SD, Bogart LM, Howerton D, et al. Cost of rapid HIV testing at 45 U.S. hospitals. AIDS Patient Care STDS. 2010;24:409-413.
27. Hutchinson AB, Farnham PG, Lyss SB, et al. Emergency department HIV screening with rapid tests: a cost comparison of alternative models. AIDS Educ Prev. 2011;23(3 suppl):58-69.
28. Hutchinson AB, Ethridge SF, Wesolowski LG, et al. Costs and outcomes of laboratory diagnostic algorithms for the detection of HIV. J Clin Virol. 2013;58(suppl 1):e2-e7.
29. Farnham PG, Hutchinson AB, Sansom SL, et al. Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep. 2008;123(suppl 3):51-62.
30. Shrestha RK, Clark HA, Sansom SL, et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep. 2008;123(suppl 3):94-100.
31. Farnham PG, Gopalappa C, Sansom SL, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64:183-189.
32. Schackman BR, Fleishman JA, Su AE, et al. The lifetime medical cost savings from preventing HIV in the United States. Med Care. 2015;53: 293-301.
33. Masciotra S, McDougal JS, Feldman J, et al. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol. 2011;52 (suppl 1):S17-S22.
34. Stout NK, Rosenberg MA, Trentham-Dietz A, et al. Retrospective costeffectiveness analysis of screening mammography. J Natl Cancer Inst. 2006;98:774-782.
35. Li R, Zhang P, Barker LE, et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33:1872-1894.
36. CDC. Integrated prevention services for HIV infection, viral hepatitis, sexually Transmitted diseases, and Tuberculosis for persons who Use drugs Illicitly: summary Guidance from CDC and the U.S. Department of health and human services MMWR Morb Mortal Wkly Rep. 2012;61: 1-40.
37. CDC. HIV infection and HIV-associated behaviors among injecting drug users - 20 cities, United States, 2009. MMWR Morb Mortal Wkly Rep. 2012;61:133-138.
38. Gray RT, Prestage GP, Down I, et al. Increased HIV testing will modestly reduce HIV incidence among gay men in NSW and would be acceptable if HIV testing becomes convenient. PLoS One. 2013;8:e55449.
39. Centers for Disease Control and Prevention and Asssociation of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. 2014. Available at http://stacks.cdc.gov/view/cdc/23447. Accessed September 24, 2014. Published June 27, 2014.
40. National Institutes of Health. Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals. Available at: http://www.nih.gov/news/health/may2015/niaid-27.htm. Published May 27, 2015. Accessed [July 14, 2015].
41. Danel C, Gabillard D, Le Carrou J. Early ART and IPT in HIV-infected African adults with high CD4 count (Temprano Trial). CROI. 2015.
42. Katz DA, Cassels SL, Stekler JD. Response to the modeling analysis by Katz et al. on the impact of replacing clinic-based HIV tests with home testing among men who have sex with men in Seattle: authors' reply. Sex Transm Dis. 2014;41:320.
43. Lucas A, Armbruster B. The cost-effectiveness of expanded HIV screening in the United States. AIDS. 2013;27:795-801.
44. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24:2705-2715.
45. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879.
46. Louie B, Liska SL, Klausner JD, et al. Reactivity of an array of HIV antibody assays with specimens from HIV acutely infected individuals. Available at: http://www.hivtestingconferencearchive.org/hivtesting2007/abstracts/abstract13.pdf. 2007.
47. Owen SM, Yang C, Spira T, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol. 2008;46:1588-1595.
48. McCormick AW, Walensky RP, Lipsitch M, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis. 2007;44:1115-1122.
49. Wilson DP, Law MG, Grulich AE, et al. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet. 2008;372:314-320.